Review
Cell & Tissue Engineering
Ellison D. Aldrich, Xiaolin Cui, Caroline A. Murphy, Khoon S. Lim, Gary J. Hooper, C. Wayne McIlwraith, Tim B. F. Woodfield
Summary: Mesenchymal stromal cells (MSCs) have been extensively studied for their paracrine signaling and immunomodulatory properties, with a focus on their role as signaling and modulating cells rather than as a cell replacement therapy. The benefits of allogeneic cells with defined characteristics in clinical settings are well recognized, with ongoing research on cell tracking techniques to further enhance the understanding of MSC activity in cartilage regeneration.
STEM CELLS TRANSLATIONAL MEDICINE
(2021)
Article
Cell & Tissue Engineering
Beth H. Shaz, Bryan D. Kraft, Jesse D. Troy, Emily Poehlein, Lingye Chen, Lynn Cheatham, Raha Manyara, Khalid Hanafy, Linda Brown, Margaret Scott, Ralph Palumbo, Frank Vrionis, Joanne Kurtzberg
Summary: This study explores the feasibility and safety of using allogeneic human umbilical cord derived mesenchymal stromal cells (hCT-MSCs) for treating COVID-19-related acute respiratory distress syndrome (ARDS). The results show that this treatment method is feasible and safe in clinical practice, without any related adverse reactions. However, further research is needed to explore its safety and efficacy.
STEM CELLS TRANSLATIONAL MEDICINE
(2023)
Article
Immunology
Haiping He, Atsuko Takahashi, Takeo Mukai, Akiko Hori, Miwako Narita, Arinobu Tojo, Tonghua Yang, Tokiko Nagamura-Inoue
Summary: Mesenchymal stromal cells (MSCs) were primed with Triptolide (TPL) to enhance their immunosuppressive abilities. TPL-primed UC-MSCs showed stronger anti-proliferative effects on activated T cells, potentially offering a novel immunosuppressive cell therapy. The upregulation of IDO-1 and induction of PD-L1 in TPL-primed UC-MSCs enhanced their immunosuppressive potency.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell & Tissue Engineering
Alexandra Cristina Senegaglia, Carmen Lucia Kuniyoshi Rebelatto, Claudio Luciano Franck, Juliana Souza Lima, Lidiane Maria Boldrini-Leite, Debora Regina Daga, Cleverson Alex Leitao, Patricia Shigunov, Ana Paula de Azambuja, Elisa Bana, Daniela Boscaro Marsaro, Bruna Schaidt, Andressa Micosky, Valderez Ravaglio Jamur, Yara Schluga, Isadora May Vaz, Lisandro Lima Ribeiro, Alejandro Correa, Paulo Roberto Slud Brofman
Summary: The COVID-19 pandemic is a significant public health event with no specific treatment available currently. Some drugs and cell-based therapies are being tested as alternatives. In this case report, the combination of tocilizumab and UC-MSC has shown to be safe and effective, providing a promising alternative for treating patients with severe acute respiratory syndrome due to SARS-CoV-2.
CELL TRANSPLANTATION
(2021)
Article
Cell & Tissue Engineering
Valentina Orticelli, Andrea Papait, Elsa Vertua, Patrizia Bonassi Signoroni, Pietro Romele, Lorena Di Pietro, Marta Magatti, Luciana Teofili, Antonietta Rosa Silini, Ornella Parolini
Summary: This study investigated the potential of human term placenta-derived amniotic membrane MSCs (hAMSC) to support the ex vivo expansion of HSC and progenitor cells. The results suggest that hAMSCs are a valuable alternative to BM-MSC for enhancing the proliferation and maintaining stemness of CB-HSC, and can improve the colony forming unit ability and long-term culture initiating cells ability, addressing the need for high HSC content in CB units available for transplantation.
STEM CELLS TRANSLATIONAL MEDICINE
(2021)
Article
Cell & Tissue Engineering
Ryan Christopher Dregalla, Jessica Ann Herrera, Edward Jeffery Donner
Summary: The study found that high levels of HCT and RBCrel significantly reduce the number of viable MSCs and increase the percentage of necrotic MSCs, becoming significant over time. Controlling HCT levels in BMC products is crucial for the treatment of inflammatory orthopedic conditions.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Cell & Tissue Engineering
William Morello, Silvia Budelli, Daniel Ari Bernstein, Tiziana Montemurro, Elisa Montelatici, Cristiana Lavazza, Luciana Ghio, Alberto Edefonti, Licia Peruzzi, Daniela Molino, Elisa Benetti, Bruno Gianoglio, Florian Mehmeti, Laura Catenacci, Jessica Rotella, Chiara Tamburello, Antonia Moretta, Lorenza Lazzari, Rosaria Giordano, Daniele Prati, Giovanni Montini
Summary: This study aimed to evaluate the safety and efficacy of cord-blood-derived mesenchymal stromal cells (CB-MSCs) in children with multi-drug resistant idiopathic nephrotic syndrome (MDR-INS). The study found that CB-MSCs treatment was safe and may have a role in immunosuppressive therapy. This preliminary experience paves the way for further studies on the effectiveness of MSCs in immune-mediated kidney diseases.
STEM CELL RESEARCH & THERAPY
(2022)
Review
Cell Biology
Susan L. Lindsay, Susan C. Barnett
Summary: The use of MSCs for transplant-mediated repair after SCI is promising, but different tissue sources of MSCs may have varying biological properties. The importance of identifying the appropriate niche-specific MSC type for SCI repair is highlighted.
Article
Cell & Tissue Engineering
Sara Bucar, Andre Dargen de Matos Branco, Marcia F. Mata, Joao Coutinho Milhano, Iris Caramalho, Joaquim M. S. Cabral, Ana Fernandes-Platzgummer, Claudia L. da Silva
Summary: The study compared the capacity of MSC from different sources to expand UCB CD34(+) cells ex vivo, with AT-derived MSC showing superior expansion potential and maintenance of primitive cells. UCM-derived MSC demonstrated inferior hematopoietic supportive capacity compared to MSC from adult tissues. Further research is needed to determine the impact of HPL on the hematopoietic supportive capacity of MSC.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Oncology
Jiasheng Wang, Farhad Sanati, Amin Firoozmand, Pingfu Fu, Merle Kolk, Jane Reese-Koc, Marcos de Lima, Kirsten Boughan, Brenda Cooper, Paolo Caimi, Molly Gallogly, Folashade Otegbeye, Benjamin Tomlinson, Leland Metheny
Summary: Combining single-unit cord blood with third-party bone marrow derived MSCs and injecting intra-osseously was shown to improve engraftment in patients undergoing allogeneic HCT. In this phase I clinical trial, 4 out of 6 high-risk hematologic malignancy patients had successful neutrophil engraftment within a median of 17.5 days, with no cases of grade 3 or higher acute GvHD observed.
FRONTIERS IN ONCOLOGY
(2023)
Article
Cell & Tissue Engineering
Xiaoyun Wu, Zhijie Ma, Yuxiao Yang, Yongxu Mu, Daocheng Wu
Summary: In this study, the safety and biodistribution of intraperitoneally transplanted umbilical cord-derived MSCs (UCMSCs) were investigated. It was found that UCMSCs cultured in a serum-free, xeno-free, and chemically defined media (UCMSCs&SXFM-CD) exhibited improved safety profiles compared to UCMSCs cultured in serum-containing media (UCMSCsSCM), with no significant toxicity or tumorigenicity observed.
STEM CELL RESEARCH & THERAPY
(2023)
Review
Pharmacology & Pharmacy
Takeo Mukai, Kenshi Sei, Tokiko Nagamura-Inoue
Summary: Studies show that MSCs exert neuroprotective and neurorestorative effects by secreting neurotrophic factors, and clinical trials have confirmed their efficacy in treating neurological disorders, highlighting the promising progress in this field.
Article
Pharmacology & Pharmacy
Mitsutoshi Ishii, Tomoshi Tsuchiya, Ryoichiro Doi, Yoichi Morofuji, Takashi Fujimoto, Hideki Muto, Takashi Suematsu, Ryoichi Mori, Keitaro Matsumoto, Takuro Miyazaki, Koichi Tomoshige, Hironosuke Watanabe, Mayumi Iwatake, Takeshi Nagayasu
Summary: The study found that adipose-derived MSCs enhanced the intercellular barrier function of lung epithelial cells, possibly through both direct adhesion and indirect paracrine effects, suggesting a strengthening of the barrier function of lung alveolar epithelium in vitro.
Review
Biochemistry & Molecular Biology
Charindu K. I. Ranmuthu, Chanuka D. S. Ranmuthu, Chalukya K. Wijewardena, Matthew K. T. Seah, Wasim S. Khan
Summary: This systematic review explores the effect of hypoxia on chondrogenic differentiation of human adult mesenchymal stromal cells (MSCs). Most studies suggest that hypoxia during the expansion or differentiation phase enhances some markers of chondrogenic differentiation in adult MSCs. However, results are inconsistent and not always confirmed at the protein level. Factors such as MSC source, donor variability, hypoxia level, exposure time, and culture methodology contribute to these inconsistent findings.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Ayse Erol, Figen Abatay Sel, Mediha Suleymanoglu, Gokhan Demirayak, Durdane Serap Kuruca, Fatma Savran Oguz
Summary: This study aimed to determine the effect of mesenchymal stem cells (MSCs) on cytokines secreted by immune system cells. Intracellular cytokine levels before and after co-culture between peripheral blood mononuclear cells (PBMCs) and MSCs were detected by flow cytometry, and supernatant cytokine levels were measured using ELISA. The results showed changes in both intracellular and supernatant cytokine levels after co-culture.
MOLECULAR BIOLOGY REPORTS
(2023)
Review
Pharmacology & Pharmacy
Rachele Ciccocioppo, Patrizia Comoli, Giuseppe Astori, Francesca del Bufalo, Malvina Prapa, Massimo Dominici, Franco Locatelli
Summary: In the last 20 years, global regulatory frameworks have been addressing the challenges posed by using cellular products as new therapeutic tools. Advanced Therapy Medicinal Products have shown potential in changing the natural course of diseases like cancers, opportunistic infections, and chronic inflammatory conditions. Over 50 cell-based products have obtained market authorization globally, highlighting the increasing importance of developing cells as innovative therapeutic vehicles.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Cell & Tissue Engineering
Rachele Ciccocioppo, Davide Gibellini, Giuseppe Astori, Martina Bernardi, Angela Bozza, Katia Chieregato, Francesca Elice, Stefano Ugel, Simone Caligola, Francesco De Sanctis, Stefania Cane, Alessandra Fiore, Rosalinda Trovato, Antonio Vella, Varvara Petrova, Giuseppe Amodeo, Monica Santimaria, Annarita Mazzariol, Luca Frulloni, Marco Ruggeri, Enrico Polati, Vincenzo Bronte
Summary: This study observed a decrease in inflammatory cells in both peripheral blood and bronchoalveolar lavage fluid, as well as a reduction in levels of pro-inflammatory cytokines like interleukin-6 and tumor necrosis factor-alpha after umbilical cord-derived MSCs treatment in COVID-19 patients. Additionally, an improvement in respiratory, renal, inflammatory, and pro-thrombotic indexes was also noted.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Oncology
Anna Dalla Pieta, Elisa Cappuzzello, Pierangela Palmerini, Annavera Ventura, Andrea Visentin, Giuseppe Astori, Katia Chieregato, Valentina Mozzo, Omar Perbellini, Maria Chiara Tisi, Livio Trentin, Carlo Visco, Marco Ruggeri, Roberta Sommaggio, Antonio Rosato
Summary: The study suggests an adoptive immunotherapy approach that combines CIK cells and CD20 antibody as an effective therapeutic strategy for aggressive B-cell malignancies, which can be rapidly translated into clinical practice without the need for genetic modifications.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Daniela Catanzaro, Gloria Milani, Angela Bozza, Martina Bernardi, Katia Chieregato, Martina Menarin, Anna Merlo, Paola Celli, Romina Belli, Daniele Peroni, Alessandro Pozzato, Gianantonio Pozzato, Fabio Angelo Raneri, Lorenzo Volpin, Marco Ruggeri, Giuseppe Astori
Summary: This study investigates the anticancer activity of quantum molecular resonance (QMR) technology for glioblastoma treatment. The results show that QMR can significantly inhibit cancer cell proliferation and reduce tumor aggressiveness. QMR appears to work by affecting DNA replication, mitotic spindle assembly, and chromosome segregation. Moreover, QMR enhances the efficacy of temozolomide when used in combination therapy.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Michele Merli, Sara Rattotti, Michele Spina, Francesca Re, Marina Motta, Francesco Piazza, Lorella Orsucci, Andres J. M. Ferreri, Omar Perbellini, Anna Dodero, Daniele Vallisa, Alessandro Pulsoni, Armando Santoro, Paolo Sacchi, Valentina Zuccaro, Emanuela Chimienti, Filomena Russo, Carlo Visco, Anna Linda Zignego, Luigi Marcheselli, Francesco Passamonti, Stefano Luminari, Marco Paulli, Raffaele Bruno, Luca Arcaini, Fdn Italiana Linfomi
Summary: This prospective study evaluated the use of genotype-appropriate DAAs in HCV-positive patients with indolent lymphomas, achieving a 100% sustained virologic response rate and a non-negligible rate of lymphoma responses. Treatment with DAAs should be considered as the first-line therapy in this setting.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Cell Biology
Omar Perbellini, Chiara Cavallini, Roberto Chignola, Marilisa Galasso, Maria T. Scupoli
Summary: This study reveals a high variability in signaling networks across different T-ALL cell lines and provides insight into the characterization of these differences using phospho-specific flow cytometry.
Article
Multidisciplinary Sciences
Katia Chieregato, Martina Bernardi, Alberta Alghisi, Rosaria Giordano, Lorenza Lazzari, Omar Perbellini, Mario Rassu, Marco Ruggeri, Giuseppe Astori
Summary: Mesenchymal stromal cells (MSC) have potential in treating aGvHD and autoimmune disorders, but their recognition mechanisms are unclear and they are not completely immunoprivileged. Developing an in vitro test and a flow cytometric assay may be an easy method for predicting treatment response.